Expanding quantitative assessment of rheumatoid arthritis in usual care

Tuulikki Sokka† & Theodore Pincus
†Author for correspondence
Jyväskylä Central Hospital, Arkisto/Tutkijat,
40620 Jyväskylä, Finland
Tel.: +358 40 735 2087;
Fax: +358 14 269 1275;
tuulikki.sokka@ksshp.fi

Quantitative measurement in rheumatoid arthritis (RA) has been greatly advanced over the last two decades. Recent research has indicated that aiming for a quantitative target value is associated with superior outcomes to usual therapy [1–3]. However, quantitative measures have been incorporated primarily into clinical research, such as clinical trials, rather than into usual clinical care. Most usual clinical rheumatology care continues to be conducted according to ‘Gestalt’ impressions, with laboratory tests as the only quantitative measures.

Clinical trials have provided invaluable data to help advance the treatment of RA and other rheumatic diseases. However, these trials involve only selected patients, as inclusion and exclusion criteria frequently leave fewer than 10% of patients eligible for participation [4,5]. Therefore, the findings may not be widely generalizable concerning RA patients in usual care.

In recent years, specialized databases have been established to assess certain patients with RA, such as those taking biological agents. These databases gather quantitative data from usual clinical care, but the patients again are selected – generally fewer than 25% of all patients. Furthermore, while the variables in these databases are 90% similar to one another, the formats are sufficiently different that the data can only be pooled for analyses with great complexity.

A few rheumatology sites have approached an ideal of collecting quantitative data from each patient at each visit in a standardized database [6–12], implementing a vision advocated by Fries in the 1970s that uniform databases from usual care of patients with rheumatic diseases could enhance more rational care and improve patient outcomes [7,13]. These efforts have provided valuable observations that are not available from clinical trials or even specialized clinical databases. However, most of these databases were derived from only one or few sites, and again were not amenable to pooling data for comparisons in a larger scale. Furthermore, quantitative measures are not available at all in certain countries. Therefore, most of the reported data concerning RA are based on a small, selected minority of all patients.

These considerations led to a program called Quantitative Patient Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis (QUEST-RA), with two objectives:

• Promote quantitative assessment of patients with rheumatic diseases in daily clinical practice

• Establish a multinational database

The initial goal was that rheumatologists in three or more clinics in different countries review 100 nonselected consecutive out-patients with RA [14]. Between January 2005 and July 2007, the program was established in 22 countries, including 5519 patients, to provide a general overview of patients who receive usual clinical care. Future directions include expanding the program to all consecutive patients at participating sites, and in additional clinics in other countries, with the ultimate goal of improving outcomes for patients in many countries.
The rheumatologists performed a 15–20-min clinical assessment involving three domains, each on a one-page form:

- Review of clinical features, including classification criteria, extra-articular features, comorbidities and relevant surgeries;
- Record of all previous and present DMARDs, adverse events and reasons for discontinuation if the DMARD is no longer taken;
- Undertaking of a 42 joint count including swollen and tender joints, as well as joints with limited motion or deformity [16].

The review also included physician global estimate of disease activity, physician report whether or not the patient had radiographic erosions and laboratory tests for erythrocyte sedimentation rate (ESR) and C-reactive protein, and rheumatoid factor values. Disease activity score (DAS)28 was calculated for current disease activity [17,18].

The patients completed a four-page expanded self-report health questionnaire that was translated into the language of each participating country according to standard methodology. The questionnaire included the Health Assessment Questionnaire (HAQ) [19] to assess functional capacity in activities of daily living, visual analog scales (VAS) for pain, global status, and fatigue, self-report joint count [20], duration of morning stiffness, lifestyle choices such as smoking and physical exercise, height and weight for body mass index and demographic data including years of education and work status.

In July 2007, the QUEST-RA database included 5519 patients from 62 sites in 22 countries [14]. The demographic characteristics are those of a typical RA cohort with 79% females, more than 90% Caucasians, a mean age of 57 years and mean education level of 11 years.

In general, patients had active disease, with a median DAS28 of 4.2. Significant variation was seen between countries (p < 0.001), ranging from around 3 in The Netherlands and Finland to 5.7 in Lithuania and 6.1 in Serbia [14]. Among 48 sites at which more than 50 patients were enrolled, by April 2007 low disease activity of DAS28 less than 3.2 was observed in more than 50% of patients at seven sites in five countries: The Netherlands, Finland, USA, Denmark and Spain (Figure 1). These data extend observations that a minority of patients at some clinical sites would be eligible for most RA clinical trials due to low disease activity [4,5]. By contrast, more than 50% of patients had high disease activity of DAS28 greater than 5.1 in five countries: Latvia, Poland, Argentina, Lithuania and Serbia.

**Figure 1. Disease activity according to DAS28 (median, IQR) in QUEST-RA per country and site.**

![Figure 1](image-url)
DAS28 and other outcome measures were associated with gross domestic product (GDP) in different countries [21]. These observations in QUEST-RA are consistent with extensive evidence that macro-economic variables concerning different nations provide significant explanation of variation in health outcomes. GDP predicts variation in overall mortality, infant mortality and life expectancy [22–24] in different countries, as well as outcomes of specific diseases, such as 5-year survival of cancer in 22 European countries [25].

Conclusion
The QUEST-RA program is the first study of patients with RA outside of clinical trials with an identical protocol in multiple locales, and provides an overview of patients who receive usual care in more than 20 countries. These data appear to be more generalized than data from single sites, specialized databases or clinical trials. The QUEST-RA database contains extensive data that can be further analyzed to better understand demographic, macroeconomic, treatment and clinical variables which may contribute to differences in clinical status among patients with RA in different countries.

Future perspective
QUEST-RA may serve as an initial step towards a practice at participating sites, to assess quantitative measures in each patient at each visit. Further efforts will be directed toward quantitative assessment of all patients at all participating sites and at additional rheumatology clinical settings using electronic tools for more feasible data collection, storage and analyses. The ultimate goal of these efforts would be to improve outcomes for patients in many countries over the next 5–10 years.

Financial & competing interests disclosure
The authors have received funding from Abbott. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Box 1. Acknowledgements: Abbott for financial support; the QUEST-RA Group.

Denmark
- Merete Lund Hetland, Copenhagen Univ Hospital at Hvidovre, Hvidovre
- Kim Harlev-Petersen, King Christian the Xth Hospital, Gråsten
- Troels Mørk Hansen, Copenhagen Univ Hospital at Herlev, Herlev

Finland
- Heidi Mäkinen, Jyväskylä Central Hospital, Jyväskylä
- Kai Immonen, Sinikka Forsberg, Jukka Lähteenmäki, North Karelia Central Hospital, Joensuu
- Reijo Luukkainen, Satakunta Central Hospital, Rauma

France
- Laure Gossec, Maxime Dougados, University René Descartes, Hôpital Cochin, Paris
- Jean Francis Mattilleff, Dijon University Hospital, University of Burgundy, Dijon
- Bernard Combe, Hôpital Lapeyronie, Montpellier
- Jean Sibilia, Hôpital Hautepierre, Strasbourg

Germany
- Gertraud Herborn, Rolf Raw, Evangelisches Fachkrankenhaus, Ratingen
- Rieke Alten, Christof Pohl, Schlusspark-Klinik, Berlin
- Gerd R Burmester, Bettina Marssmann, Charite – University Medicine Berlin, Berlin

Ireland
- Barry Bresnihan, St. Vincent University Hospital, Dublin
- Patricia Minnock, Our Lady’s Hospice, Dublin
- Eithne Murphy, Claire Sheehy, Edel Quirke, Connolly Hospital, Dublin
- Joe Devlin, Shafeeq Alraqi, Waterford Regional Hospital, Waterford

Italy
- Massimiliano Cazzato, Stefano Bombardieri, Santa Chiara Hospital, Pisa
- Gianfranco Ferraccioli, Alessia Morelli, Catholic University of Sacred Heart, Rome
- Maurizio Cutolo, University of Genova, Genova, Italy
- Fausto Salaffi, Andrea Stancati, University of Ancona, Ancona

The Netherlands
- Suzan MM Verstappen, University Medical Center Utrecht, Utrecht, Netherlands
- Margriet Huismann, Sint Franciscus Gasthuis Hospital, Rotterdam
- Monique Hoekstra, Medisch Spectrum Twente, Enschede

www.futuremedicine.com
Box 1. Acknowledgements: Abbott for financial support; the QUEST-RA Group.

Poland
- Stanislaw Sierakowski, Medical University in Bialystok, Bialystok
- Maria Majdan, Medical University of Lublin, Lublin
- Wojciech Romanowski, Poznan Rheumatology Center in Srem, Srem
- Wieslaw Tusztowicz, Military Institute of Medicine, Warszaw
- Danuta Kapolska, Sileian Hospital for Rheumatology and Rehabilitation in Ustroń Slaski, Ustroń Slaski
- Stefan Sadkiewicz, Szpital Wojewodzki im. Jana Biziela, Bydgoszcz
- Danuta Zarowny-Wierzchinska, Wojewodzki Zespol Reumatologiczny im. dr Jadwigi Titz-Kosko, Sopot

Spain
- Antonio Naranjo, Hospital de Gran Canaria Dr. Negrin, Las Palmas
- Jaime Calvo-Alen, Hospital Sierra Llanana Ganzo, Torrelavega
- Miguel Belmonte, Hospital General de Castellon, Castellon

Sweden
- Eva Barclund, Uppsala University Hospital, Uppsala
- Rolf Oden, Margareth Liveborn, Centrallnorrlands, Västerås
- Ann-Carin Holmquist, Hudiksvall Medical Clinic, Hudiksvall

UK
- Peter Taylor, Catherine McClinton, Charing Cross Hospital, London
- Anthony Woolf, Ginny Chorghade, Royal Cornwall Hospital, Truro
- Ernest Chop, Stephen Kelly, Kings College Hospital, London

Turkey
- Feride Gogus, Gazi Medical School, Ankara
- Recep Tunc, Meram Medical Faculty, Konya
- Selda Celic, Cerrahpasa Medic Faculty, Istanbul

Serbia
- Vlado Skakic, Aleksandar Dimic, Jovan Nedovic, Aleksandra Stankovic, Rheumatology Institut, Niska Banja

USA
- Theodore Pincus, Christopher Swearingen, Vanderbilt University, Nashville, TN
- Yusuf Yazici, NYU Hospital for Joint Diseases, New York, NY
- Martin Bergman, Taylor Hospital, Ridley Park, PA

Argentina
- Sergio Toleza, Santiago Agueru, Sergio Orellana Barrera, Soledad Retamozo, Hospital San Juan Bautista, Catamarca
- Paula Alba, Cruz Laisoan, Alejandra Bahini, Eduardo Albiero, Hospital of Cordoba, Cordoba

Estonia
- Raili Muller, Reet Kause, Marika Tammaru, Riina Kallikorm, Tartu University Hospital, Tartu
- Tony Pets, East Tallinn Central Hospital, Tallinn
- Ivo Valtar, Center for Clinical and Basic Research, Tallinn

Latvia
- Daina Anderson, Pauli Stradiuna Clinical University Hospital, Riga

Lithuania
- Sigita Stropuviene, Jolanta Dadoniene, Institute of Experimental and Clinical Medicine at Vilnius University, Vilnius
- Asta Baranauskaite, Kaunas University Hospital, Kaunas

Hungary
- Bernadette Rajkovich, Pali Géher, Semmelweis University of Medical Sciences, Budapest
- Ilona Utitaly, Polyclinic of the Hospital for Brothers of St. John of God in Budapest, Budapest

Greece
- Alexandros A. Drouts, Sofia Exarchou, University of Ioannina, Ioannina
- H.M.Moutsopoulos, Afrodite Tsiropoula, School of Medicine, National University of Athens, Athens
- Fotini N Skopouli, Maria Vamvrommati, Eureclinic Hospital, Athens

Canada
- Jurri Lazovskis, Riverside Professional Center, Sydney, NS

Study center
- Tauliku Sikka, Jyväskylä Central Hospital, Jyväskylä, Medicare Oy, Äänekoski, Finland
- Hannu Kautiainen, Medicare Oy, Äänekoski, Finland
- Theodore Pincus, New York University Hospital for Joint Diseases, New York, NY, USA
Bibliography

Papers of special note have been highlighted as of interest (*) to readers.


Affiliations

- Tuulikki Sokka
  Jyväskylä Central Hospital, Arkiolo/Turki jaht, 40620 Jyväskylä, Finland
  Tel.: +358 40 735 2087;
  Fax: +350 14 269 1275;
  tuulikki.sokka@kalp.fi

- Theodore Pincus
  New York University Hospital for Joints Diseases, New York, NY, USA
  Tel.: +1 212 598 6417;
  Fax: +1 212 598 6168;
  tepincus@gmail.com